Thomas Klein

Title: Innovations by Thomas Klein in the Field of Inflammatory Disease Treatment.

Introduction

Thomas Klein is an accomplished inventor based in Constance, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of inflammatory diseases. His innovative approach combines the use of a PDE4 inhibitor with a conventional NSAID, aiming to enhance therapeutic outcomes while minimizing side effects.

Latest Patents

Klein holds a patent for a unique combination of a NSAID and a PDE-4 inhibitor. This invention focuses on the combined use of a PDE4 inhibitor and a conventional NSAID in treating inflammatory diseases and inflammation-associated disorders. The goal is to reduce gastrointestinal side effects, such as gastric erosions and ulcers, which are commonly linked to conventional NSAID use. A preferred PDE4 inhibitor for this combination is roflumilast or a derivative thereof, while diclofenac or a derivative serves as the conventional NSAID.

Career Highlights

Thomas Klein is associated with Nycomed GmbH, where he has been instrumental in advancing research and development in pharmaceutical innovations. His work has garnered attention for its potential to improve patient outcomes in the treatment of inflammatory conditions.

Collaborations

Klein collaborates with notable professionals in his field, including his coworker Hans-Peter Kley. Their combined expertise contributes to the ongoing development of effective treatment options for patients suffering from inflammatory diseases.

Conclusion

Thomas Klein's innovative work in combining a PDE4 inhibitor with a conventional NSAID represents a significant advancement in the treatment of inflammatory diseases. His contributions continue to shape the future of medical therapies aimed at reducing side effects while enhancing efficacy.